433 related articles for article (PubMed ID: 38218202)
1. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
[TBL] [Abstract][Full Text] [Related]
2. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
Moon JH; Jeong S; Jang H; Koo BK; Kim W
EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
Aliment Pharmacol Ther; 2024 Apr; ():. PubMed ID: 38664876
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
[TBL] [Abstract][Full Text] [Related]
7. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
Ochoa-Allemant P; Marrero JA; Serper M
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
[TBL] [Abstract][Full Text] [Related]
8. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
[TBL] [Abstract][Full Text] [Related]
9. Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.
Nasr P; Wester A; Ekstedt M; Strandberg R; Kechagias S; Shang Y; Widman L; Hagström H
Clin Gastroenterol Hepatol; 2024 May; 22(5):1048-1057.e2. PubMed ID: 38237695
[TBL] [Abstract][Full Text] [Related]
10. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
Lee BP; Dodge JL; Terrault NA
Hepatology; 2024 Mar; 79(3):666-673. PubMed ID: 37732946
[TBL] [Abstract][Full Text] [Related]
11. New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
Canivet CM; Boursier J; Loomba R
Semin Liver Dis; 2024 Feb; 44(1):35-42. PubMed ID: 38531378
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
[TBL] [Abstract][Full Text] [Related]
13. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
14. Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes.
Chen YT; Chen TI; Yang TH; Yin SC; Lu SN; Liu XR; Gao YZ; Lin CJ; Huang CW; Huang JF; Yeh ML; Huang CF; Dai CY; Chuang WL; Yang HI; Yu ML; Lee MH
Am J Gastroenterol; 2024 Apr; ():. PubMed ID: 38534155
[TBL] [Abstract][Full Text] [Related]
15. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population based study with 26.7 years of follow-up.
Kwak M; Kim HS; Jiang ZG; Yeo YH; Trivedi HD; Noureddin M; Yang JD
Hepatology; 2024 May; ():. PubMed ID: 38739848
[TBL] [Abstract][Full Text] [Related]
16. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
Loomba R; Wong VW
Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study.
Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Fukao T; Shimizu M; Yamamoto M
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398471
[TBL] [Abstract][Full Text] [Related]
18. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
Staufer K; Stauber RE
Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
[TBL] [Abstract][Full Text] [Related]
19. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M
J Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38629681
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
Kalligeros M; Vassilopoulos A; Vassilopoulos S; Victor DW; Mylonakis E; Noureddin M
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1330-1332.e4. PubMed ID: 37949334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
